Document is current

Article History

Received: 8 May 2021

Accepted: 23 August 2021

First Online: 8 September 2021

Declarations

:

: The study has been approved by the institutional review board of the Technical University of Munich, Munich, Germany (Approval Number: 162/15). Written informed consent was obtained from all subjects before enrollment.

: Not applicable.

: AB has nothing to disclose. CB received grants and/or personal fees from AbbVie, Gilead Sciences, Janssen-Cilag, ViiV Healthcare, and MSD during the study and outside the submitted work. CC received grants and/or personal fees from ViiV Healthcare during the study and outside the submitted work. CDS received grants and/or personal fees from Gilead Sciences, Janssen-Cilag, ViiV Healthcare/GSK, MSD, and Healthcare/GSK during the course of this study and from AbbVie, Aperion, Eli Lilly, Formycon, and Molecular partners outside the submitted work. EW received grants and/or personal fees from AbbVie, Gilead Sciences, Janssen-Cilag, ViiV Healthcare, and MSD during the study and outside the submitted work. HB has nothing to disclose. HH received personal fees from TUM and IZAR during the conduct of the study, and personal fees from Janssen Cilag, Gilead, MSD, ViiV Healthcare, and AbbVie outside the submitted work. HJS received grants and/or personal fees from Gilead Sciences, Janssen-Cilag, ViiV Healthcare/GSK, MSD, Theratechnologies, and Heidelberg Immunotherapeutics during the course of this study and outside the submitted work. IK received grants and/or personal fees from AbbVie, Gilead Sciences, Janssen-Cilag, ViiV Healthcare, and MSD during the study and outside the submitted work. JS received grants and/or personal fees from Gilead Sciences, Janssen-Cilag, and AbbVie outside the submitted work. TK has nothing to disclose.